サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1790292

細胞・遺伝子治療の臨床試験市場規模、シェア、動向分析レポート：フェーズ別、適応症別、地域別、セグメント予測、2025年～2033年

Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III), By Indication (Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases), By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
細胞・遺伝子治療の臨床試験市場規模、シェア、動向分析レポート：フェーズ別、適応症別、地域別、セグメント予測、2025年～2033年
出版日: 2025年07月14日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞・遺伝子治療臨床試験市場サマリー

市場は主に、遺伝子医療における技術革新の加速ペースと、先進治療に対する規制当局の支援の増加によって牽引されています。CRISPRのようなゲノム編集技術の開発や、ウイルスおよび非ウイルスベクター送達システムの画期的な進歩により、研究者は希少な遺伝性疾患、がん、自己免疫疾患に対する高度に標的化された治療薬候補を開発できるようになりました。FDAやEMAなどの規制機関は、CGT開発を支援するために、早期承認パスウェイ、希少疾病用医薬品指定、RMAT（再生医療先進治療）指定を導入しました。これらの優遇措置は、新規CGT製品を開発する企業の時間とコスト負担を大幅に軽減し、初期段階の試験開始を促しています。

さらに、CGT開発に注力するバイオテクノロジー企業、大手製薬会社、学術研究センター間の資金流入や戦略的提携が市場開拓を後押ししています。特にベンチャーキャピタルや官民連携によるこのような資金面での勢いは、臨床試験スポンサーがパイロット試験から多施設国際試験へと規模を拡大することを可能にしています。Bluebird Bio社、CRISPR Therapeutics社、Beam Therapeutics社などの企業は、鎌状赤血球症、CAR-T療法、遺伝子編集ベースの腫瘍学パイプラインなどの分野で多数の第I/II相試験を開始しています。さらに、これらの治療法の安全性、投与量、長期的な有効性を検証する必要性から、CGT試験に合わせた専門のCROや試験インフラに対する需要が高まっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 細胞・遺伝子治療臨床試験市場：変数、動向、範囲

  • 市場系統の見通し
  • 細胞・遺伝子治療臨床試験市場力学
  • 技術的情勢
  • 価格モデル分析
  • 細胞・遺伝子治療臨床試験市場：分析ツール

第4章 細胞・遺伝子治療臨床試験市場：フェーズ別の推定・動向分析

  • セグメントダッシュボード
  • 世界の細胞・遺伝子治療臨床試験市場のフェーズ別変動分析
  • 世界の細胞・遺伝子治療臨床試験市場規模と動向分析（フェーズ別、2021～2033年）
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第5章 細胞・遺伝子治療臨床試験市場：適応症別の推定・動向分析

  • セグメントダッシュボード
  • 世界の細胞・遺伝子治療臨床試験市場の適応別変動分析
  • 世界の細胞・遺伝子治療臨床試験市場規模と動向分析（適応症別、2021～2033年）
  • 腫瘍学
  • 心臓病学
  • 中枢神経系
  • 筋骨格
  • 感染症
  • 皮膚科
  • 内分泌、代謝、遺伝
  • 免疫学と炎症
  • 眼科
  • 血液学
  • 消化器内科
  • その他

第6章 細胞・遺伝子治療臨床試験市場：タイプ、製品、試験、サンプル、最終用途別の地域推定・動向分析

  • 地域別市場ダッシュボード
  • 世界地域市場のスナップショット
  • 市場規模、予測動向分析、2021～2033年：
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業分類
  • 細胞・遺伝子治療臨床試験市場シェア分析（2024年）
  • 企業プロファイル
    • IQVIA
    • ICON Plc
    • LabCorp
    • Charles River Laboratories
    • PAREXEL International Corp.
    • Syneos Health
    • Medpace
    • Thermo Fisher Scientific, Inc.
    • Novotech
    • Veristat, LLC
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Cell and Gene Therapy Clinical Trials market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 4 North America Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 5 U.S. Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 6 U.S. Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 7 Canada Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 8 Canada Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 9 Mexico Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 10 Mexico Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 11 Europe Cell and Gene Therapy Clinical Trials market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 12 Europe Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 13 Europe Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 14 UK Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 15 UK Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 16 Germany Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 17 Germany Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 18 France Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 19 France Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 20 Italy Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 21 Italy Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 22 Spain Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 23 Spain Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 24 Norway Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 25 Norway Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 26 Denmark Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 27 Denmark Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 28 Sweden Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 29 Sweden Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 30 Asia Pacific Cell and Gene Therapy Clinical Trials market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 31 Japan Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 32 Japan Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 33 China Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 34 China Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 35 India Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 36 India Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 37 Australia Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 38 Australia Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 39 South Korea Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 40 South Korea Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 41 Thailand Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 42 Thailand Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 43 Latin America Cell and Gene Therapy Clinical Trials market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 44 Latin America Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 45 Latin America Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 46 Brazil Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 47 Brazil Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 48 Argentina Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 49 Argentina Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 50 MEA Cell and Gene Therapy Clinical Trials market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 51 MEA Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 52 MEA Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 53 South Africa Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 54 South Africa Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 55 Saudi Arabia Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 56 Saudi Arabia Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 57 Kuwait Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 58 Kuwait Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 59 UAE Cell and Gene Therapy Clinical Trials market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 60 UAE Cell and Gene Therapy Clinical Trials market estimates and forecasts, by indication, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cell And Gene Therapy Clinical Trials market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market outlook, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 Cell And Gene Therapy Clinical Trials market dynamics
  • Fig. 19 Total R&D drug pipeline size, 2021 - 2024
  • Fig. 20 Total drug pipeline by development phase, 2024
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 PESTEL analysis
  • Fig. 23 Cell And Gene Therapy Clinical Trials market phase outlook: Segment dashboard
  • Fig. 24 Cell And Gene Therapy Clinical Trials market, by phase segment: Market share, 2025 & 2033
  • Fig. 25 Phase I market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Phase II market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Phase III market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Phase IV market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Cell And Gene Therapy Clinical Trials market indication outlook: Segment dashboard
  • Fig. 30 Cell And Gene Therapy Clinical Trials market, by indication segment: Market share, 2024 & 2033
  • Fig. 31 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Cardiology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 CNS market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Musculoskeletal market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Dermatology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Endocrine, metabolic, genetic market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Immunology & inflammation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Ophthalmology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Hematology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Gastroenterology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Regional market: Key takeaways
  • Fig. 44 Regional marketplace: Key takeaways
  • Fig. 45 North America Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 U S Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Canada Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Mexico Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Europe Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 UK Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Germany Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 France Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Italy Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Spain Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Denmark Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Sweden Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Asia Pacific Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Japan Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 China Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 India Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Korea Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Thailand Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Latin America Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Brazil Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Argentina Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 MEA Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 South Africa Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Saudi Arabia Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 UAE Cell and Gene Therapy Clinical Trials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 96 Market participant categorization
  • Fig. 97 Heat map analysis
目次
Product Code: GVR-4-68039-409-7

Cell And Gene Therapy Clinical Trials Market Summary

The market is primarily driven by the accelerating pace of innovation in genetic medicine and increasing regulatory support for advanced therapies. Advancements in genome editing technologies such as CRISPR, as well as breakthroughs in viral and non-viral vector delivery systems, have enabled researchers to develop highly targeted therapeutic candidates for rare genetic disorders, cancers, and autoimmune diseases. Regulatory bodies, including the FDA and EMA, have introduced accelerated approval pathways, orphan drug designations, and RMAT (Regenerative Medicine Advanced Therapy) designations to support CGT development. These incentives have significantly reduced the time and cost burden for companies developing novel CGT products, encouraging the launch of early-phase trials.

Furthermore, the influx of funding and strategic partnerships between biotech firms, large pharmaceutical companies, and academic research centers focused on CGT development is driving the market growth. This financial momentum, especially from venture capital and public-private collaborations, is enabling clinical trial sponsors to scale up from pilot studies to multi-site international trials. Companies like Bluebird Bio, CRISPR Therapeutics, and Beam Therapeutics, numerous Phase I/II trials are being initiated in areas such as sickle cell disease, CAR-T therapies, and gene editing-based oncology pipelines.Moreover, the need to validate safety, dosing, and long-term efficacy of these therapies has increased demand for specialized CROs and trial infrastructure tailored to CGT studies.

Global Cell And Gene Therapy Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell and gene therapy clinical trials market report based on phase, indication, and region:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiology
  • CNS
  • Musculoskeletal
  • Infectious diseases
  • Dermatology
  • Endocrine, metabolic, genetic
  • Immunology & inflammation
  • Ophthalmology
  • Hematology
  • Gastroenterology
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Norway
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cell And Gene Therapy Clinical Trials Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Cell And Gene Therapy Clinical Trials Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
      • 3.2.1.1. Growing Interest in Cell and Gene Therapy
      • 3.2.1.2. Adoption Of New Technology in Clinical Research
      • 3.2.1.3. Increasing Investments And R&D Funding
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Recruitment Obstacles
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Cell And Gene Therapy Clinical Trials Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. Cell And Gene Therapy Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Cell and Gene Therapy Clinical Trials Market Phase Movement Analysis
  • 4.3. Global Cell and Gene Therapy Clinical Trials Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cell And Gene Therapy Clinical Trials Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Cell and Gene Therapy Clinical Trials Market Indication Movement Analysis
  • 5.3. Global Cell and Gene Therapy Clinical Trials Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cardiology
    • 5.5.1. Cardiology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. CNS
    • 5.6.1. CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Musculoskeletal
    • 5.7.1. Musculoskeletal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Infectious diseases
    • 5.8.1. Infectious diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Dermatology
    • 5.9.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Endocrine, metabolic, genetic
    • 5.10.1. Endocrine, metabolic, genetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.11. Immunology & inflammation
    • 5.11.1. Immunology & inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.12. Ophthalmology
    • 5.12.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.13. Hematology
    • 5.13.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.14. Gastroenterology
    • 5.14.1. Gastroenterology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.15. Others
    • 5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cell And Gene Therapy Clinical Trials Market: Regional Estimates & Trend Analysis by Type, Product, Test, Sample, End Use

  • 6.1. Regional Market Dashboard
  • 6.2. Global Regional Market Snapshot
  • 6.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Competitive Scenario
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Competitive Scenario
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Competitive Scenario
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Cell And Gene Therapy Clinical Trials Market Share Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. IQVIA
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. ICON Plc
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. LabCorp
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Charles River Laboratories
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. PAREXEL International Corp.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Syneos Health
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Medpace
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Thermo Fisher Scientific, Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Novotech
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Veristat, LLC
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives